Medical Crossfire®: Improving Survival in HR-Positive HER2 Negative Metastatic Breast Cancer – Advances in Es...
December 12, 2024
Register Now!
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
IPSS-del(5q) Scoring System Enhances Risk Assessment in MDS With 5q Deletions
At the 2024 ASH Annual Meeting, findings suggested that the IPSS-del(5q) Scoring System may more effectively identify risks in MDS with isolated 5q deletions compared to standard MDS scoring systems.
Socioeconomic Factors Impact Access to Allogeneic Stem Cell Transplant in AML
Socioeconomic factors significantly impact access to allogeneic hematopoietic stem cell transplant in patients with acute myeloid leukemia, with certain groups less likely to receive this potentially lifesaving treatment.
B019 CAR T-Cell Therapy Shows High Efficacy, Safety in Relapsed/Refractory B-ALL
December 11th 2024Updated phase 2 trial data presented at the 2024 ASH Annual Meeting show that the novel bicistronic CD19/CD22-directed CAR T-cell therapy is safe, durable, and highly effective in children with relapsed/refractory B-ALL.
Axi-Cel Efficacy in R/R Indolent Non-Hodgkin Lymphoma Sustained at 5 Years
December 10th 2024“These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or refractory indolent non-Hodgkin lymphoma, with curative potential in patients with follicular lymphoma,” said Sattva S. Neelapu, MD.
Novel BTK Degrader BGB-16673 Shows Activity in WM and CLL/SLL
The novel Bruton tyrosine kinase degrader BGB-16673 shows promise in relapsed/refractory Waldenström macroglobulinemia previously exposed to BTK inhibitors, and in heavily pretreated patients with R/R chronic lymphocytic leukemia/small lymphocytic lymphoma.
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Belantamab Mafodotin Triplet Improves OS, Stakes a Claim as New SOC in R/R Multiple Myeloma
The combination of belantamab mafodotin and bortezomib/dexamethasone improved overall survival over daratumumab plus the same doublet in patients with relapsed/refractory multiple myeloma.
Isatuximab Plus VRd Enhances MRD Negativity and Responses in Transplant-Ineligible NDMM
The phase 3 IMROZ trial showed isatuximab plus VRd and Rd maintenance improved MRD negativity and responses versus VRd alone in transplant-ineligible newly diagnosed multiple myeloma.